Shanghai Henlius Biotech (HKSE:02696) Pre-Tax Income : HK$353 Mil (TTM As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Shanghai Henlius Biotech's pretax income for the three months ended in Jun. 2024 was HK$0 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was HK$353 Mil. Shanghai Henlius Biotech's pretax margin was %.

During the past 7 years, Shanghai Henlius Biotech's highest Pretax Margin was 11.25%. The lowest was -6740.39%. And the median was -169.09%.

Shanghai Henlius Biotech Pre-Tax Income Historical Data

The historical data trend for Shanghai Henlius Biotech's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Pre-Tax Income Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-973.45

-1,177.78

-1,171.50

-774.87

622.99

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
Pre-Tax Income	Get a 7-Day Free Trial													-393.46	-	180.02	172.63	-

Competitive Comparison of Shanghai Henlius Biotech's Pre-Tax Income

For the Biotechnology subindustry, Shanghai Henlius Biotech's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Henlius Biotech's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Pre-Tax Income falls into.

Shanghai Henlius Biotech Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Shanghai Henlius Biotech's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	789.487	+	0	+	-120.905	+	8.91	+	-54.5
	=	623

Shanghai Henlius Biotech's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	0	+	0	+	0	+	0	+	0
	=	0

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$353 Mil.

Shanghai Henlius Biotech (HKSE:02696) Pre-Tax Income Explanation

Shanghai Henlius Biotech's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0	/	0
	=	%

During the past 7 years, Shanghai Henlius Biotech's highest Pretax Margin was 11.25%. The lowest was -6740.39%. And the median was -169.09%.

Shanghai Henlius Biotech Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Ubs Group Ag
Golden Valley Value Select Master Fund	2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited	2301 Trustee
Lvc Sg Management Pte. Ltd.	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lin Lijun	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Qatar Investment Authority	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines